Dyadic and Medytox to co-develop Covid-19 variant fighting vaccines

By PBR Staff Writer

US-based global biotechnology company Dyadic International has announced the expansion of its partnership with South Korea-based global research biopharmaceutical company Medytox to co-develop C1 manufactured Covid-19 vaccines.